June 22, 2025
Operating Assets

With Trials In Motion, Cash To 2027, Can Kyverna’s Next Data Drop Turn The Stock Around? – Kyverna Therapeutics (NASDAQ:KYTX)

HC Wainwright upgraded Kyverna Therapeutics Inc. KYTX, citing three upcoming data sets through mid-2025. In its first quarter 2025 earnings released, the company highlighted: Enrollment is complete in the registrational Phase 2 KYV-101 trial for stiff person syndrome (SPS). The trial is on track for topline data and a biologics license application (BLA) filing is

Read More
Operating Assets

FDA Rejects Aldeyra’s Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns – Aldeyra Therapeutics (NASDAQ:ALDX)

The U.S. Food and Drug Administration (FDA) on Thursday issued a Complete Response Letter for Aldeyra Therapeutics, Inc.’s ALDX resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for dry eye disease. The FDA stated that the NDA “failed to demonstrate efficacy in adequate and well-controlled studies in treating ocular symptoms associated

Read More